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INTRODUCTION
Human papillomavirus (HPV) is a wide family of DNA vi-
ruses that can infect basal epithelial cells of the skin or
inner-lining tissues (Burd, 2003). The majority of sexually
active men and women will acquire genital HPV infection
at some point during their lifetime. In 2008, it was esti-
mated that 610 000 cancers in men and women were attrib-
uted to HPV infection worldwide (Albero et al., 2014).
Based on association with cervical cancer and precursor le-
sions, HPV can also be classified as high-risk (HR-HPV)
and low-risk (LR-HPV) oncogenic types (Burd, 2003; Mu-
ñoz et al., 2003). LR-HPV types, such as HPV 6 and 11,
can cause common genital warts or benign hyper-proli-
ferative lesions with very limited tendency to malignant
progression, while infection with HR-HPV types, highlight-
ing HPV 16 and 18, is associated with the occurrence of
pre-malignant and malignant cervical lesions (Coscia et al.,
2015). HPV-16 and HPV-18 types are also associated with
many penile, cervical, vulvar, anal, and head and neck car-
cinomas, and contribute to over 40% of oral cancers
(Shukla et al., 2009; Coscia et al., 2015).
Most HPV infections are “cleared” by the immune system
and do not result in clinical diseases in healthy individuals;
however, in cases of immune system suppression infections
can lead to development of malignancies (Brendle et al.,
2014).
Innate immune response, which includes dendritic, Langer-
hans, natural killer cells and keratinocytes, becomes the first
line of defence against the infection. These cells are impor-
tant in promoting adaptive immune response against HPV
infection (Scott et al., 2001; Stanley and Sterling, 2014).
Also, helper T-lymphocytes (CD 4+) play a sufficient role
in response against HPV infection. CD4+ T cell responses
to capsid protein are necessary for optimal antibody and cy-
totoxic T cell production (Frazer, 2009).
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Kidney transplant recipients have higher incidence of human papillomavirus (HPV)-related malig-
nancies, but studies on the natural history of HPV infection are insufficient, especially regarding in
male recipients. The aim of this study was to evaluate the course of high-risk HPV (HR-HPV) in-
fection after kidney allograft transplantation in male recipients: to estimate frequency and activity
of HR-HPV infection under immune system suppression. Twenty male renal recipients (age 20 –
68) were enrolled in this investigation and examined in dynamics. Peripheral EDTA-blood sam-
ples and urine samples were collected from each patient 2 weeks, 6 months and 12 months after
transplantation. Polymerase chain reaction (PCR) with consensus primers was used for initial de-
tection of high range HPV types, a commercial qPCR kit for detection of HR-HPV load in urine
samples and ELISA for detection of serum IgG class antibodies to HR-HPV L1-capsid protein.
Overall, combining molecular (HR-HPV genomic sequences detected by real-time PCR) and se-
rological studies (IgG class antibodies to HR-HPV L1-capsids’ protein), high frequency of HR-
HPV infection among male kidney transplant recipients (9/20; 45%) was showed. However, the
majority of HR-HPV positive recipients (7/9; 78%) showed signs of infection clearance. It means
that, despite the applied immune suppressive therapy, the host’s immune system is capable of
dealing with HR-HPV infection up to the 12th month after transplantation. However, the sample
size should be increased to enable through statistical analysis before final conclusions are made.
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Immunosuppressive treatment of organ transplant recipients
is associated with an increase in the occurrence of HPV-
related anogenital (pre)malignancies (Meeuwis et al., 2015).
Kidney transplant recipients have a higher incidence of
HPV-related malignancies. However, studies on the natural
history of HPV infection are insufficient, especially regard-
ing male recipients. While immunosuppressive regimens
improve the overall survival of renal transplant recipients,
they also contribute to the long-term complications of post-
transplant malignancies (Genzer et al., 2012). In males, on-
cogenic HPV types are associated with penile, anal, oropha-
ryngeal, and non-melanoma skin cancers (Grulich et al.,
2007). Of significance for male recipients is that these
HPV-associated cancers are also known to be significantly
higher in the post kidney transplantation period (Halpert et
al., 1986; Buell et al., 2005).
The aim of this study was to evaluate the course of high-risk
HPV (HR-HPV) infection after kidney allograft transplanta-
tion in male recipients: to estimate frequency and activity of
HR-HPV infection under immune system suppression.
MATERIALS AND METHODS
Twenty male renal recipients (age 20–68) who received kid-
ney allograft during 2013–2014 were enrolled in this inves-
tigation and examined in dynamics. The recipients had the
following diagnosis: autosomal dominant polycystic kidney
(n = 6), chronic glomerulonephritis (n = 3), haemolytic ure-
mic syndrome (n = 1), diabetic nephropathy (n = 2), focal
segmental glomerulosclerosis (n = 1), hypertensive nephro-
pathy (n = 3), reflux nephropathy (n = 1), urate nephropathy
(n = 1), ANCA associated vasculitis with lung and kidney
damage — rapidly progressive glomerulonephritis (n = 1),
and chronic kidney disease with unspecified aetiology (n =
1).
All patients had received induction immunosuppression
therapy with monoclonal or polyclonal antibodies and triple
supportive immunosuppression therapy consisting of gluco-
corticoids, anti-proliferative drugs and calcineurin inhibi-
tors.
The main inclusion criteria were availability of peripheral
EDTA blood and urine samples, and possibility to examine
the recipient at three times — 2 weeks, 6 months and 12
months after transplantation.
Aliquots of 200 µl blood plasma were collected from EDTA
peripheral blood samples for further serological testing.
Cells from urine were collected by centrifugation and
washed with PBS three times. Blood plasma samples and
cells from urine were stored at –70 °C
DNA from urine samples was extracted using the phe-
nol-chloroform method.
Beta ()-globin PCR with appropriate primers were used to
determine the quality of the isolated DNA (Vandamme et
al., 1995).
Polymerase chain reaction (PCR) with consensus primers
GP5+/GP6+ was used for initial detection of high range
HPV types (HR-HPV and LR-HPV types) (Jacobs et al.,
1995) and the HPV High Risk Screen Real-TM Quant com-
mercial qPCR kit (Sacace, Italy) for quantitative detection
of 12 types of HR-HPV (16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, and 59) in recipient urine DNA samples. Type-
specific PCR was used to detect HPV-16 and HPV-18 ge-
nomic sequences in recipient urine DNA samples according
to Leiros et al., 2005. Sample contamination in PCR was
excluded by using negative controls (negative for HPV
DNA and water control).
The ELISA commercial kit (MyBioSource, USA) was used
to detect IgG class antibodies to HR-HPV L1-capsids’ pro-
tein in recipient plasma (presence of these antibodies is as-
sociated with HR-HPV clearance) (Stanley, 2008; Skiba et
al., 2006). Parameters characterising cellular immunity
were taken from patient medical histories in order to ana-
lyse their immune system status and its influence on HR-
HPV infection activity.
The study was approved by the Ethics Committee of Rîga
Stradiòð University, and written consent was obtained from
all patients.
RESULTS
48 (80%) of 60 urine DNA samples taken from 20 male kid-
ney renal recipients in dynamics (2 weeks, 6 months and 12
months after transplantation) were positive on -globin,
showing good DNA quality, and were used in PCR. Initial
PCR results with consensus primers (allowing to detect 23
HPV types) showed that 8/20 (40%) of the recipients were
positive on HPV genomic sequences in urine DNA samples.
In 3/8 of recipients’ urine samples viral DNA was detected
two weeks after transplantation, two of them continued
showing and two additional recipients showed presence of
HPV genomic sequences in urine DNA samples (4/8) six
months after transplantation. Twelve months after trans-
plantation five recipients were positive on HPV genomic se-
quences in urine DNA samples (2/4 that were positive after
6 months and another 3 that were negative at earlier sam-
pling times). Interestingly, only one recipient had HPV
genomic sequences in urine DNA samples during the entire
study period (2 weeks, 6 and 12 months after transplanta-
tion).
qPCR results showed that two of eight recipients were posi-
tive on HR-HPV genomic sequences. One recipient showed
clinically significant (according to manufacturer’s protocol,
3log10 viral copies/10
5 cells or more) HR-HPV load –
6.87log10 viral copies/10
5 cells two weeks after transplanta-
tion. However, HR-HPV genomic sequences were not de-
tectable in this recipient at 6 and 12 months. However, urine
DNA samples of this recipient were positive on consensus
HPV genomic sequence during the entire observation peri-
od. A second recipient showed clinically significant HR-
HPV load (3.85log10 viral copies/10
5) six months after
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transplantation, which was no longer detectable 12 months
after transplantation, but results of PCR with consensus
primers showed presence of HPV genomic sequences at that
time.
Type-specific PCR results showed that none of the male
kidney transplant recipients was positive on HPV-16 or
HPV-18 genomic sequences.
Serological study showed that 7 of 20 recipients had IgG
class antibodies to HR-HPV L1-capsid protein, while urine
DNA samples of five of them were negative in PCR with
consensus HPV as well as in HR-HPV qPCR. All 7 recipi-
ents were HR-HPV seropositive 12 months after transplan-
tation. At the same time, two recipients with high HR-HPV
load lacked IgG class antibodies to HR-HPV L1-capsid pro-
tein during the whole period of observation.
Overall, combining qPCR (2/20) and serological results
(7/20), signs of HR-HPV infection was shown in 9/20
(45%) recipients.
To compare parameters of recipients, cellular immunity ex-
amination of their medical histories was made and data on
immunocompetent cell absolute counts in 1 mm3 were re-
trieved (12 months after transplantation). Mean absolute
counts for immunocompetent cells were evaluated for re-
cipients with and without IgG class antibodies to HR-HPV
L1-capsid protein. At 12 months after transplantation, mean
counts of CD4+ (T helpers) and CD19+ cells (B lympho-
cytes) tended to be higher in the recipient group with IgG
class antibodies to HR-HPV L1-capsid protein than in the
recipient group without antibodies (not significant, p = 0.66
and p = 0.62, respectively) (Table 1). Also, the CD4+/CD8+
index tended to be higher in recipients with IgG class anti-
bodies to HR-HPV L1-capsid protein than in recipients
without them (1.56 ± 1.28 vs. 1.15 ± 0.66, p = 0.44), show-
ing better immune system function (Table 1).
Evaluation of recipient medical histories did not show pres-
ence of any specific HR-HPV-associated complications.
The most common complications in HR-HPV positive
recipients were secondary anaemia (6/9; 66%) and arterial
hypertension (9/9; 100%), which are not associated with
HR-HPV infection. In one HR-HPV positive recipient, oral
candidiasis and II type diabetes were observed and in an-
other, HR-HPV positive recipient — decreased kidney cysts
were present.
DISCUSSION
The aim of investigation was to determine frequency and
activity of HR-HPV infection in Latvian male kidney trans-
plant recipients under immune system suppression; this has
been investigated worldwide, but not in Latvia.
During this investigation we encountered with several prob-
lems: 1) there is no standardisation in detection of HR-HPV
(a variety of methods and systems for HR-HPV detection
exist); 2) today over 15 types of HR-HPV are known, and
therefore, it is difficult to type all HR-HPV and to evaluate
the oncogenic potential of each of them.
Another problem was in collection of the samples — two
weeks after renal transplantation was the earliest time peri-
od when collection of material from patients for the first
HR-HPV testing was possible, because a large proportion of
the recipients had anuria before the operations.
This study presents the first data on HPV infection fre-
quency among Latvian male kidney transplant recipients.
HPV genomic sequences were found in 40% (8/20) of re-
cipient urine samples (using consensus primers), of which
two showed additionally clinically significant HR-HPV
load, estimated using a commercial qPCR kit. Three of 20
recipients (15%) had HPV genomic sequences in urine sam-
ple two weeks after transplantation, but it could not be ex-
cluded that this infection was present already before trans-
plantation, as a short time had passed since surgery and we
were not able to carry out HPV infection screening before
transplantation due to anuria in the majority of patients.
Five other recipients (25%) were positive 6 and 12 months
after transplantation, showing that the majority of recipients
have HPV reactivation or are infected in the later period af-
ter transplantation. Considering that one of two recipients
also showed clinically significant HR-HPV load (3.85log10
viral copies/105) on the 6th month after transplantation, we
suggest that this period of time is the most important for re-
cipients; however, activation of HR-HPV in the early period
of immunosuppressive treatment after transplantation also is
possible.
Two recipients positive on HR-HPV genomic sequences
were negative on IgG class antibodies to HR-HPV
L1-capsid protein and of seven seropositive recipients only
two were positive in PCR with a consensus HPV genomic
sequence. In this case, the mentioned antibodies might have
appeared during viral clearance and show past infection
(Skiba et al., 2006; Stanley, 2008). Another explanation is
that anti HR-HPV IgG class antibody presence and absence
of HR-HPV genomic sequences in urine DNA samples indi-
T a b l e 1
MEAN ABSOLUTE COUNTS OF IMMUNOCOMPETENT CELLS’
POPULATIONS (1 MM3) IN KIDNEY TRANSPLANT RECIPIENTS







Leu 6680 ± 2010 6240 ± 2120 0.66
Ly 1880 ± 700 1660 ± 660 0.49
CD3+ 1515 ± 525 1438 ± 578 0.76
CD4+ 611 ± 327 692 ± 418 0.66
CD8+ 595 ± 268 521 ± 241 0.53
CD16+ 271 ± 232 170 ± 117 0.21
CD19+ 75 ± 47 92 ± 81 0.62
CD95+ 891 ± 371 861 ± 354 0.86
CD4+/CD8+ 1.15 ± 0.66 1.56 ± 1.28 0.44
* p value of immunocompetent cells parameters changes between two
groups, IgG negative and IgG positive.
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cates another site of persistence or a low and HR-HPV load
that is undetectable using the qPCR kit.
Also, information on immunocompetent cell parameters
from clinical histories showed that seropositve recipients
develop antibodies against HR-HPV L1 capsid protein on
the 12th month after transplantation; at that time, mean ab-
solute cell counts of CD4+ and CD19+ cells (cell subpopu-
lations involved in antibody production) were higher than in
recipients without IgG antibodies (not significant: p = 0.66
and p = 0.62, respectively).
At present there is still no convincing and consensual HPV
screening methodology for kidney transplant patients.
Nowadays, many researchers suggest using first-void urine
samples for HPV testing as an alternative and non-invasive
method for screening (Golijow et al., 2005; Pathak et al.,
2014). However, our study results show that 20% of urine
DNA samples have poor quality and need to be excluded
from further examination. Therefore, a urine sample is not a
fully reliable template for HPV screening and should be
supported additionally with other methods and results.
Overall, combining molecular and serological studies this
study showed a high frequency of HR-HPV infection
among male kidney transplant recipients (9/20; 45%); the
majority of HR-HPV positive recipients (7/9; 78%) did not
show signs of infection clearance. This means that, despite
the applied immunosuppressive therapy, the hosts immune
system is capable of dealing with HR-HPV infection up to
the 12th month after transplantation, and occurrence of IgG
class antibodies to HR-HPV L1-capsid protein in recipients
could be used as a positive prognostic marker suggesting
that the host immune system is capable of dealing with
HR-HPV infection.
Epidemiological data provided by Forman et al (2012) show
that Eastern Europe has a higher HPV prevalence rate
(21.4%) than in Northern, Western and Southern Europe
(10.0%, 9.0%, and 8.8%, respectively). Lower prevalence
occurs in Western Asia and Northern America (1.7% and
4.7%, respectively), and the highest in the Caribbean
(35.4%) (Forman et al., 2012).
According to literature data, a high range of genital HR-
HPV prevalence (3–20%) has been observed in immuno-
competent men (Nyitray et al., 2011; Alfonso et al., 2016;
Cai et al., 2016); however, in immunocompromised men
the prevalence of genital HR-HPV infection is much higher
and can reach 51% (Li et al., 2016). This is in concordance
with results of this study, which however included a small
group of recipients (n = 20).
The majority of male recipients who were positive on
HR-HPV infection (7/9; 77.7%) were at age between 50 and
66.
To evaluate the full influence of immunosuppressive ther-
apy on HR-HPV infection, more detailed examination of
each case should be made. However, the immunosup-
pressive therapy applied from beginning in the majority of
cases was the same for all recipients, but which was
changed individually based on developed complications.
Differences in immunosuppressive therapy can have differ-
ent effect on the host’s immune system, including anti-viral
response.
It is important to evaluate the oncogenic potential of all
HR-HPV types in immunosuppressed hosts, but it is very
difficult to carry out such investigations due to the high di-
versity of virus types (over 15 types). We conducted type-
specific PCR for HPV 16 and HPV 18 in male recipients, of
which none were positive.
To draw final conclusions on HR-HPV infection activity
and its oncogenic potential, further investigation should be
carried out with an increased sample size for thorough sta-
tistical testing.
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AUGSTA RISKA CILVÇKA PAPILOMAS VÎRUSA INFEKCIJA VÎRIEÐU DZIMUMA NIERU TRANSPLANTÂTA SAÒÇMÇJIEM
LATVIJÂ
Nieru transplantâcijas recipientiem ir lielâka saslimstîba ar cilvçka papilomas vîrusa (HPV) izraisîtiem ïaundabîgiem audzçjiem. Îpaði trûkst
pçtîjumu par HPV infekciju vîrieðiem. Ðî pçtîjuma mçríis bija novçrtçt augsta riska HPV (HR-HPV) infekciju kursu pçc nieru
transplantâcijas vîrieðu recipientiem: novçrtçt HR-HPV infekciju bieþumu un aktivitâti imûnsistçmas nomâkuma gadîjumâ. Ðajâ pçtîjumâ
tika iesaistîti 20 vîrieði (vecumâ 20–68 gadi) pçc nieru transplantâcijas, un viòu turpmâkâ novçroðana notika dinamikâ. Perifçro asiòu un
urîna paraugi tika savâkti 2 nedçïas, 6 mçneðus un 12 mçneðus pçc nieru transplantâcijas. Polimerâzes íçdes reakcija (polymerase chain re-
action, PCR) ar konsensus praimeriem tika izmantota, lai sâkotnçji noteiktu plaðu HPV tipu spektru, bet qPCR komplekts, lai noteiktu
HR-HPV klâtbûtni DNS paraugos, kuri izdalîti no recipientu urîna. Iegûtâs molekulârâs atradnes tika papildinâtas ar imunoloìisko râdîtâju
datiem. Kopumâ, apvienojot molekulâros un seroloìiskos rezultâtus, pçtîjums ir parâdîjis bieþu HR-HPV infekcijas sastopamîbu vîrieðu
dzimuma nieru transplantâcijas recipientu vidû (9/20; 45%), tomçr vairumâ HR-HPV infekcijas gadîjumu (7/9; 78%) parâdîjâs vîrusa
eliminâciju pazîmes. Tas nozîmç, ka, neraugoties uz lietoto imûnsupresîvo terapiju, pacientu imûnsistçma tomçr spçj tikt galâ ar HR-HPV
infekciju 12 mçneðu laikâ pçc transplantâcijas, tomçr, lai veiktu statistisko apstrâdi un varçtu izdarît galçjus secinâjumus, ir jâpalielina
pçtîjumâ iekïauto pacientu un izmeklçto paraugu skaits.
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